Smoldering Inflammation in MS
Part of paid clinical trials in St Louis, Missouri.
- Sponsor
- Washington University School of Medicine
- Study ID
- NCT06591429
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Radiotracer [11C]-CS1P1 — RADIATIONRadiotracer used in PET/CT scans of the head and neck Dose range: 12-17 mCi
- Radiotracer [11C]-DPA-713 — RADIATIONRadiotracer used in PET/CT scans of the head and neck Dose range:15-20 mCi
- anti-CD20 MS treatment — DRUGMS treatment taken indepenently after initial testing
- Radiotracer [12F]-FDG — RADIATIONused in PET/CT scans of the head and neck Dose: 5-7 mCi
Study Details
The goal of this observational study is to learn about inflammation in those with relapsing remitting Multiple Sclerosis (MS). The main questions it aims to answer are: * How does abnormal neural inflammation compare to cellular and molecular inflammation in MS? * Once treated, why does abnormal inflammation persist?
Key Dates
- Start date
- Jun 19, 2024
- Status verified
- Dec 2025
- Primary completion
- Jun 30, 2027
- Completion
- Jun 30, 2027
Study Design
- Enrollment
- 25 participants (estimated)
Arms
- Arm: ParticipantsAdults with MS taking part in this study.
Primary Outcome Measure
Volume of Distribution (Vt) of DPA-713 and CS1P1 and Cerebral metabolic rate of glucose (CMRglc) in white matter lesions and normal appearing white matter before and after treatment. [ Time Frame: 1 year ]
Central Contacts
- Matthew Brier, MD, PhD314-362-7666
- Nicole Shelley, MA314-730-0516
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Barnes Jewish Center for Clinical Imaging Research | St Louis | Missouri | 63110 | Nicole E Shelley, MA Matthew R Brier, MD, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in St Louis, MO
By condition
By specialty
By research site
Related Studies
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)PHASE1 · Recruiting · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Birmingham, Alabama
- A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 YearsPHASE2 · Recruiting · ModernaTX, Inc. · Boston, Massachusetts
- This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.Recruiting · Washington University School of Medicine · St Louis, Missouri